New data shows GeniusPure Alpha-GPC boosts cognitive and exercise performance after just one dose. With 90% yield and unmatched stability, NNB Nutrition is setting a new standard for rapid, noticeable results.
A new clinical trial has demonstrated that NNB Nutrition’s GeniusPure™ Alpha-GPC can significantly improve cognitive performance and exercise output after just a single dose,[1] marking the first study to show acute benefits of Alpha-GPC supplementation in healthy individuals.
The dietary supplement industry has long sought ingredients that can deliver immediate, noticeable effects while maintaining stability and quality. Alpha-glycerylphosphorylcholine (Alpha-GPC) has been a popular choice for both cognitive and physical performance enhancement, but traditional forms have faced challenges with stability and potency. NNB Nutrition developed GeniusPure to address these limitations, offering a more stable form that can achieve up to 90% yield compared to the standard 50% found in other products.
To validate GeniusPure’s effects, researchers conducted a randomized, double-blind, placebo-controlled crossover study examining both cognitive and physical performance measures. The results were recently published in preprint form by Dr. Chad Kerksick, President of the International Society of Sports Nutrition (ISSN).
Subscribe to PricePlow's Newsletter and Alerts on These Topics
GeniusPure Study Details
Before beginning, we must disclaim that this study is currently in pre-print status and has not yet been peer-reviewed, although that process is underway. With that said, it’s from a research team that has numerous journal publications under their belt.
NNB Nutrition is proud to announce GeniusPure Alpha-GPC, which is patent-pending stabilized alpha-GPC at 70% or 90%!
-
Purpose
The study aimed to evaluate the acute effects of two different doses of GeniusPure Alpha-GPC on cognitive function and exercise performance in healthy, resistance-trained males.
-
Methods
Twenty resistance-trained men (average age 31.3 years) participated in the study, which used a randomized, double-blind, placebo-controlled, crossover design. Each participant completed three separate trial conditions:[1]
- High-dose (HD): 630mg Alpha-GPC (delivered as 700mg of 90% GeniusPure)
- Low-dose (LD): 315mg Alpha-GPC (delivered as 350mg of 90% GeniusPure)
- Placebo (PL): Resistant dextrin
Participants were assessed for cognitive performance using the Stroop test, Flanker test, and N-Back test, along with various physical performance measures including bench press throws and vertical jumps. These tests are explained below for those who are unfamiliar, and after that we get into the results.
The Cognitive Test Methods Used
The study employed three well-validated cognitive assessments:
- Stroop Test: A foundational cognitive assessment that measures selective attention, cognitive flexibility, and processing speed.
Participants must name the color of a word while ignoring the word itself (for example, the word “RED” printed in blue ink – the correct answer would be “blue”). This test evaluates one’s ability to suppress automatic responses (reading the word) in favor of a less automatic task (naming the color).[2]
- Flanker Test: Evaluates attention and inhibitory control by measuring how well participants can focus on a central stimulus while ignoring surrounding distracting stimuli.
Participants respond to the direction of a central arrow while ignoring “flanking” arrows that may point in the same direction (congruent) or opposite direction (incongruent). This test reveals how well someone can maintain focus and filter out distractions.[3]
- N-Back Test: A sophisticated assessment of working memory where participants must indicate when a current stimulus matches one from “n” steps earlier in a sequence.
In a 1-back task, they identify if the current item matches the previous one; in a 2-back task, they match it to the item shown two steps ago. This measures both working memory capacity and information processing ability.[4,5]
Timeline Schematic of Study Design and Procedures
-
Results
The study revealed several significant findings:[1]
Cognitive Performance
- Both doses improved Stroop test performance compared to placebo
- High-dose group showed 150% greater improvement in total Stroop score vs. placebo
- Low-dose group demonstrated 108% better Stroop performance vs. placebo
- Processing speed increased 140% with high dose and 50% with low dose vs. placebo
Chad Kerksick, President of ISSN (International Society of Sports Nutrition), Joins PricePlow for Episode #141 to talk about sports performance research and to recap ISSN 2024. This is part 1 of a 2 part series!
The GeniusPure groups demonstrated remarkable improvements in mental processing and attention. The high-dose (630mg) group’s 150% improvement in Stroop test performance represents a dramatic enhancement in participants’ ability to process information quickly while managing conflicting stimuli. This was complemented by the 140% increase in processing speed, suggesting that participants could not only perform the cognitive tasks better, but do them significantly faster.[1]
Even the low-dose (315mg) group showed impressive gains, with the 108% improvement in Stroop performance and 50% boost in processing speed demonstrating that even half doses of GeniusPure can deliver meaningful cognitive benefits.[1]
The fact that both dosing protocols yielded significant improvements over placebo indicates a reliable dose-response relationship, giving formulators flexibility in how they incorporate GeniusPure into their products.
Physical Performance
- High-dose significantly increased upper-body peak force production vs. placebo (p = 0.043)
- Low-dose improved lower-body peak force production compared to high-dose
- Both doses showed 2.5-10% improvements in various force and power production measures
The physical performance data revealed nuanced but important benefits across different aspects of muscular performance. In the upper body assessments, the high-dose GeniusPure group’s significant improvement in peak force production (p = 0.043)[1] suggests enhanced neuromuscular efficiency, possibly due to optimized acetylcholine availability at the neuromuscular junction. This improvement in force production could translate to better performance in strength-based activities and resistance training.
The lower body results were particularly interesting, with the low-dose group showing superior peak force production compared to the high dose. This unexpected finding suggests potential dose-dependent effects that vary by muscle group or movement pattern, but more data is always useful before making such conclusions.
The overall 2.5-10% improvements in force and power production metrics across both dosing protocols indicate that GeniusPure can enhance multiple aspects of physical performance, from explosive power to maximal force production. These improvements, while modest in percentage terms, could make meaningful differences in athletic performance where small margins often separate success from failure.
Real-World Implications: Acute Benefits
This study is particularly significant because it demonstrates acute benefits from a single dose of GeniusPure. As Dr. Kerksick recently discussed on Episode #141 and Episode #142 of the PricePlow Podcast, this kind of immediate effect is crucial for supplements meant to enhance workout performance or cognitive function. Additionally, as revealed in Episode #152 with Shawn Wells and Dustin Elliott, NNB Nutrition has more research planned for GeniusPure.
The findings suggest that GeniusPure would be particularly effective in:
- Pre-workout supplements
- Nootropic formulations
- Energy drinks
- Gaming supplements
These applications are especially relevant given GeniusPure’s superior stability and higher yield compared to traditional Alpha-GPC ingredients, as discussed in our initial coverage of GeniusPure.
Conclusion: GeniusPure Takes the Alpha-GPC Throne
Shawn Wells and Dustin Elliott of NNB Nutrition join the PricePlow Podcast for Episode #152 to discuss innovative ingredients that capture ongoing trends like GLP-1 and MPS. We also get into Dustin’s trip to China, NNB’s participation in XPO NRG with MitoPrime, and Shawn’s psychedelic experiences and his post-trip supplement stack.
This clinical trial represents a significant advancement in Alpha-GPC research, being the first (that we’re aware of) to demonstrate acute benefits in healthy individuals without added confounding ingredients. The study’s robust methodology and clear results suggest that GeniusPure offers immediate cognitive and physical performance benefits while solving the stability issues that have historically challenged Alpha-GPC supplementation.
The implications for supplement formulators are substantial – GeniusPure provides a more stable, higher-yield option that can deliver noticeable benefits from the first dose. As more research emerges from NNB Nutrition’s pipeline, we expect to see GeniusPure’s applications continue to expand across the supplement industry.
You can sign up for our NNB Nutrition and GeniusPure news alerts below, and then see all other articles published about GeniusPure:
Comments and Discussion (Powered by the PricePlow Forum)